Vivani Medical to spin-off neurostim business Cortigent

Vivani Medical to spin-off neurostim business Cortigent as public company
Vivani was created in 2022 when subdermal drug implant company Nano Precision Medical merged with implantable visual prosthetics company Second Sight Medical Products. The new com
EXCLUSIVE: Vivani Medical To Spin Off Cortigent Neurostimulation Business To Create Better Focus On Individual Entities And Shareholder Value
Vivani Medical, Inc. (NASDAQ:VANI) said it intends to spin off Cortigent, Inc., a division that develops brain implant devices to help people recover critical body functions, as an independent publicly-traded company.
Vivani to spin out neurostim business, focus on GLP-1 implant
The company wants to create two focused companies dedicated to driving current and future value in their respective therapeutic areas. Vivani aims to continue advancing its miniature GLP-1 therapeutic implants. The spin-off would enable Cortigent to continue progressing its brain implant devices to help people recover critical body functions.
Vivani looking to get slim with Cortigent neurostimulation spin
The Vivani Medical Inc. combination appears to be over less than three years since its inception after the company reported plans to spin off Cortigent, the division that develops brain implants. Vivani said it plans to create two focused companies dedicated to driving current and future value in their respective therapeutic areas.
Vivani Medical intends to spin off Cortigent division
Vivani Medical (VANI) announced that it intends to spin off Cortigent, a division that develops brain implant devices to help people recover
Vivani Medical to divest its neurostimulation devices business
Vivani Medical (NASDAQ:VANI) said on Wednesday that it intends to divest its Cortigent unit, which builds neurostimulation devices. The company said that this spin-off will help Vivani focus on the development of miniature,
Vivani Medical Achieves 1st Implant & Full Enrollment in Overweight Trial
By Karen Roman Vivani Medical, Inc. (Nasdaq: VANI) announced it finished the placement of NPM-115, its GLP-1 (exenatide) ...
Medical Device Network on MSN1d
Vivani treats first patient with long-lasting drug implant for weight loss
A day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the ...
EXCLUSIVE: Vivani Medical Announces First Implant In Early-Stage Human Study Of GLP-1 Implant For Obesity
Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.
Vivani Medical announces 1st GLP-1 implant in Liberate-1 clinical trial
Vivani Medical (VANI) announced the successful administration of its first GLP-1 or exenatide, implant in the LIBERATE-1 clinical trial. This ...
Drug Delivery Business1d
Vivani reports first human GLP-1 implant for weight loss in adults
Vivani Medical (Nasdaq:VANI) announced today that it successfully administered the first GLP-1 implant in its LIBERATE-1 ...
Vivani Medical Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults
Vivani Medical, Inc. (NASDAQ: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing ...
Business Wire3d
Vivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business
Cortigent’s Orion ® artificial vision system, which is in development to treat blindness, completed an initial 6-year clinical study in 2024, with encouraging safety and efficacy results ...